Racial disparities in the surgical management of non-small cell lung cancer
The surgical management of non-small cell lung cancer (NSCLC) in U.S. hospitals varies widely depending on the race of the patient, according to a new study.
Cancer
9 hours ago |
not rated yet |
0
Diabetes drug could hold promise for lung cancer patients
Ever since discovering a decade ago that a gene altered in lung cancer regulated an enzyme used in therapies against diabetes, Reuben Shaw has wondered if drugs originally designed to treat metabolic diseases ...
Cancer
Jan 29, 2013 |
not rated yet |
0
|
Study examines drug resistance in ALK positive lung cancer
Scientists from the University of Colorado Cancer Center have once again advanced the treatment of a specific kind of lung cancer. The team has documented how anaplastic lymphoma kinase (ALK) positive advanced non-small cell ...
Cancer
Jan 19, 2012 |
not rated yet |
0
Genetic vulnerability of lung cancer to lay foundation for new drug options
Physician-researchers at UT Southwestern Medical Center have identified a vulnerability of certain lung-cancer cells – a specific genetic weakness that can be exploited for new therapies.
Cancer
Apr 04, 2013 |
not rated yet |
0
|
Biomarkers discovered that may help predict response to drugs targeting KRAS-mutated NSCLC
Scientists have identified biomarkers that may help predict whether patients with KRAS-mutated non-small cell lung cancer (NSCLC) will respond to concurrent treatment with an MEK inhibitor and a PI3 kinase inhibitor, a drug ...
Cancer
Apr 08, 2013 |
not rated yet |
0
Painless skin rash predicts survival benefit from latest lung cancer drug, study finds
(Medical Xpress)—Elderly patients with advanced non small cell lung cancer (NSCLC) who developed a rash within 28 days of receiving the targeted drug erlotinib (Tarceva) survived on average 6.2 months, c ...
Cancer
Oct 17, 2012 |
not rated yet |
0
Tissue platinum concentrations linked to response in NSCLC
(HealthDay) -- For patients with non-small-cell lung cancer (NSCLC) who undergo neoadjuvant platinum-based chemotherapy, tissue platinum concentrations correlate positively with improved outcome, according ...
Cancer
Aug 14, 2012 |
not rated yet |
0
Researchers report first success of targeted therapy in most common non-small cell lung cancer
A new study by an international team of investigators led by Dana-Farber Cancer Institute scientists is the first to demonstrate that chemotherapy and a new, targeted therapy work better in combination than chemotherapy alone ...
Cancer
Nov 28, 2012 |
not rated yet |
0
|
Novel test identifies patients most likely to benefit from ALK inhibition therapy
Approximately one in 20 patients with non-small cell lung carcinoma (NSCLC) has chromosomal aberrations targeting the anaplastic lymphoma kinase (ALK) gene. This has considerable implications for treatment because these patients ...
Medical research
Dec 12, 2012 |
not rated yet |
0
|
Drug resistance biomarker could improve cancer treatment
Cancer therapies often have short-lived benefits due to the emergence of genetic mutations that cause drug resistance. A key gene that determines resistance to a range of cancer drugs has been reported in a study published ...
Cancer
Nov 21, 2012 |
not rated yet |
0
|
Ganetespib showed activity in KRAS-mutant NSCLC as monotherapy and in combinations
The investigational drug ganetespib, a synthetic second-generation Hsp90 inhibitor, slowed the growth of cancer cells taken from non-small cell lung cancer tumors with a mutation in the KRAS gene. The drug was even more active ...
Cancer
Jan 11, 2012 |
not rated yet |
0
Sorafenib effective in patients with non-small cell lung cancer, but low survival rates reported
Sorafenib was effective in patients with non-small cell lung cancer and a KRAS mutation, but survival rates were reportedly "unsatisfactory," according to data presented at the AACR-IASLC Joint Conference on Molecular Origins ...
Cancer
Jan 10, 2012 |
not rated yet |
0
EGFR mutation not prognostic factor in non-small cell lung cancer
Recent studies have demonstrated that molecular-targeted agents, such as epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI), may prolong survival of selected patients based on tumor biomarkers. The presence ...
Cancer
Jan 15, 2013 |
not rated yet |
0
Patients with EGFR exon 20 insertions have poorer prognosis
Exon 20 insertions are the third most common family of epidermal growth factor receptor (EGFR) mutations found in non–small-cell lung cancer (NSCLC). Little is known about cancers harboring these mutations aside from their ...
Cancer
Jan 15, 2013 |
not rated yet |
0
Greater representation of elderly patients in Phase III trials are needed
The median age of patients diagnosed with advanced non–small-cell lung cancer (NSCLC) has steadily increased over the recent years and is presently 70 years. Despite this, the elderly are significantly underrepresented ...
Cancer
Feb 22, 2013 |
not rated yet |
0
